Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2A phase 1 randomized clinical trial

[1] Tan E(2020)Global impact of COVID-19 infection requiring admission to the intensive care unit: a systematic review and meta-analysis Chest 159 524-536

[2] Song J(2020)The promise of mRNA vaccines: a biotech and industrial perspective NPJ Vaccines 5 11-107

[3] Deane AM(2017)RNActive Methods Mol Biol 1499 89-1520

[4] Plummer MP(2017) technology: generation and testing of stable and immunogenic mRNA vaccines Lancet 390 1511-1318

[5] Jackson NAC(2017)Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial NPJ Vaccines 2 29-569

[6] Kester KE(2021)Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines Vaccine 39 1310-1149

[7] Casimiro D(2021)First proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial NPJ Vaccines 6 57-280

[8] Gurunathan S(2020)mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents Nat Microbiol 5 562-11734

[9] DeRosa F(2020)Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses Acta Pharmacol Sin 41 1141-577

[10] Rauch S(2020)Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 Cell 181 271-E7357

[1] Tan E(2020)Global impact of COVID-19 infection requiring admission to the intensive care unit: a systematic review and meta-analysis Chest 159 524-536

[2] Song J(2020)The promise of mRNA vaccines: a biotech and industrial perspective NPJ Vaccines 5 11-107

[3] Deane AM(2017)RNActive Methods Mol Biol 1499 89-1520

[4] Plummer MP(2017) technology: generation and testing of stable and immunogenic mRNA vaccines Lancet 390 1511-1318

[5] Jackson NAC(2017)Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial NPJ Vaccines 2 29-569

[6] Kester KE(2021)Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines Vaccine 39 1310-1149

[7] Casimiro D(2021)First proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial NPJ Vaccines 6 57-280

[8] Gurunathan S(2020)mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents Nat Microbiol 5 562-11734

[9] DeRosa F(2020)Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses Acta Pharmacol Sin 41 1141-577

[10] Rauch S(2020)Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 Cell 181 271-E7357